期刊论文An update on patent issues regarding antibody–drug conjugates: Patents复制

DOI:复制

文献链接:复制

其他信息:

U Storz
nature biotechnology, 2026
nature.com
… A decade on, while the basic principles discussed in the first review of the patent
landscape of antibody–drug conjugates still apply, the ADC landscape has dramatically
evolved and diversified. … Patent-wise, following the basic formula antibody–linker–toxin,
each of the three elements can confer novelty and non-obviousness on an ADC-related
invention. In regard to reciting antibodies, linkers and toxins in a patent claim, different
levels of abstraction (Table 1) provide different options for protecting a final ADC product. Of …